Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers
Open Access
- 22 November 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , e1289-e1301
Abstract
Background: Thyroid cancers are among the growing list of cancer types that are resistant to immune-checkpoint inhibitor monotherapy. Although T-cell infiltration is common in follicular cell-derived thyroid cancers, tumor mutation burden is low. The antigenic potential of thyroid cancers is unknown. Methods: To investigate the anti-tumor T-cell response in thyroid cancer, we expanded tumor-infiltrating lymphocytes (TIL) from primary thyroid tumors and tumor-involved lymph nodes (TILN). Putative neoantigens and both tissue-associated and tumor-associated antigens were identified by targeted sequencing and RNA-seq. HLA typing was performed for all patients, and neoantigen binding potential was predicted for each patient using NetMHCpan 4.1 and NetMHCIIpan 4.0 algorithms. In parallel, T-cell receptor β sequencing was performed to detect T-cell clonal expansions in patient-matched primary tumors and TILN. TIL reactivity to tumor-associated antigens and neoantigens was determined in vitro by interferon γ ELISA and flow cytometry. Results: Tumor-infiltrating T cells were evident in all thyroid tumors and readily expanded ex vivo. Shared clones were present in primary thyroid tumors and matched TILN in all patients tested, constituting 1% to 10% of the sequenced clones in 6/8 patients. T-cell reactivity to thyroid tissue-specific proteins, thyroid peroxidase and thyroglobulin, was observed in 84.6% (11/13) and 69.2% (9/13) patients, respectively. A BrafV600E-specific T-cell response was evident in 80% (4/5) BrafV600E+ patients. T cells reactive to gene fusion-derived neoantigens were detected in patients with TPR-NTRK1+ and CCDC6-RET+ thyroid cancer. Conclusion: Our studies confirm the presence of tumor antigen-specific T cells in patients with thyroid cancer and encourage further exploration of T cell-targeted immunotherapies for patients with progressive, treatment refractory thyroid cancer.Keywords
Funding Information
- National Institutes of Health (P30CA046934)
- Cancer Center, University of Colorado (SCR_022035)
- Bioinformatics and Biostatistics Shared Resource (SCR_021983)
- Genomics Shared Resource (SCR_021984)
- British Thyroid Foundation
- Mary Moody Northen Endowment (U01AI090905)
- Cancer League of Colorado (193539-PN)
This publication has 58 references indexed in Scilit:
- Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid CarcinomaJAMA Oncology, 2024
- Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid CarcinomaJAMA Oncology, 2024
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyThe Lancet, 2024
- NTRK fusion events and targeted treatment of advanced radioiodine refractory thyroid cancerJournal of Cancer Research and Clinical Oncology, 2023
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 studyThe Lancet Oncology, 2020
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 PatientsCancer Cell, 2018
- Defining KIR and HLA Class I Genotypes at Highest Resolution via High-Throughput SequencingThe American Journal of Human Genetics, 2016
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Integrated Genomic Characterization of Papillary Thyroid CarcinomaCell, 2014
- “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapyInternational Journal of Cancer, 2010